QNCX Quince Therapeutics Inc

Price (delayed)

$1.12

Market cap

$18.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.9

Enterprise value

$386,829

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 9

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence ...

Highlights
The debt has shrunk by 98% QoQ and by 98% YoY
The net income has soared by 61% QoQ and by 46% YoY
The equity has soared by 144% QoQ but it has decreased by 16% YoY
The quick ratio has contracted by 45% YoY

Key stats

What are the main financial stats of QNCX

QNCX stock price

How has the Quince Therapeutics stock price performed over time
Intraday
8.74%
1 week
-4.27%
1 month
-8.2%
1 year
-89.72%
YTD
-96.66%
QTD
10.89%

Financial performance

How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$116.42M
Net income
-$33.04M
Gross margin
N/A
Net margin
N/A
QNCX's operating income has dropped by 131% since the previous quarter and by 102% year-on-year
The net income has soared by 61% QoQ and by 46% YoY

Price vs fundamentals

How does QNCX's price correlate with its fundamentals

Growth

What is Quince Therapeutics's growth rate over time

Valuation

What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 41% since the previous quarter and by 29% year-on-year
The equity has soared by 144% QoQ but it has decreased by 16% YoY
QNCX's P/B is 95% below its 5-year quarterly average of 7.2

Efficiency

How efficient is Quince Therapeutics business performance
The ROIC has dropped by 112% year-on-year but it has increased by 27% since the previous quarter
Quince Therapeutics's ROA has soared by 51% from the previous quarter and by 24% YoY

Dividends

What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QNCX.

Financial health

How did Quince Therapeutics financials performed over time
QNCX's total assets is 143% greater than its total liabilities
QNCX's total liabilities has plunged by 92% from the previous quarter and by 88% YoY
QNCX's total assets has dropped by 75% year-on-year and by 72% since the previous quarter
The debt is 98% lower than the equity
The equity has soared by 144% QoQ but it has decreased by 16% YoY
QNCX's debt to equity has surged by 104% since the previous quarter but it has dropped by 98% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.